APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Solid Tumor Drug Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchSolid Tumor Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumor Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Solid Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumor Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Solid Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Solid Tumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Solid Tumor Drug market include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Solid Tumor Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Solid Tumor Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Solid Tumor Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Solid Tumor Drug market.

Solid Tumor Drug Segment by Company

Johnson & Johnson

Pfizer Inc

GlaxoSmithKline plc.

Baxter

AstraZeneca

F. Hoffmann-La Roche Ltd.

Eli Lilly and Company

Celgene Corporation

Bristol-Myers Squibb Company

Biogen

Amgen Limited & Amgen Ireland Limited

Abbott Laboratories

Solid Tumor Drug Segment by Type

Small Molecules

Biologics

Solid Tumor Drug Segment by Application

Radiology

Neurology

Oncology

Others

Solid Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Solid Tumor Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Solid Tumor Drug key companies, revenue, market share, and recent developments.

3. To split the Solid Tumor Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Solid Tumor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Solid Tumor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Solid Tumor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Solid Tumor Drug industry.

Chapter 3: Detailed analysis of Solid Tumor Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Solid Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Solid Tumor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Solid Tumor Drug Industry Trends Table 2. Solid Tumor Drug Industry Drivers Table 3. Solid Tumor Drug Industry Opportunities and Challenges Table 4. Solid Tumor Drug Industry Restraints Table 5. Global Solid Tumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Solid Tumor Drug Revenue Share by Company (2021-2026) Table 7. Global Solid Tumor Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Solid Tumor Drug Key Company Manufacturing Base & Headquarters Table 9. Global Solid Tumor Drug Company, Product Type & Application Table 10. Global Solid Tumor Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Solid Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecules Table 15. Significant Companies of Biologics Table 16. Global Solid Tumor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Solid Tumor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Solid Tumor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Solid Tumor Drug Sales Value Share by Type (2021-2026) Table 20. Global Solid Tumor Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Radiology Table 22. Significant Companies of Neurology Table 23. Significant Companies of Oncology Table 24. Significant Companies of Others Table 25. Global Solid Tumor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Solid Tumor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Solid Tumor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Solid Tumor Drug Sales Value Share by Application (2021-2026) Table 29. Global Solid Tumor Drug Sales Value Share by Application (2027-2032) Table 30. Global Solid Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Solid Tumor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Solid Tumor Drug Sales Value Share by Region (2021-2026) Table 33. Global Solid Tumor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Solid Tumor Drug Sales Value Share by Region (2027-2032) Table 35. Global Solid Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Solid Tumor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Solid Tumor Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Solid Tumor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Solid Tumor Drug Sales Value Market Share by Country (2027-2032) Table 40. Johnson & Johnson Company Information Table 41. Johnson & Johnson Business Overview Table 42. Johnson & Johnson Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Johnson & Johnson Solid Tumor Drug Product Portfolio Table 44. Johnson & Johnson Recent Development Table 45. Pfizer Inc Company Information Table 46. Pfizer Inc Business Overview Table 47. Pfizer Inc Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Pfizer Inc Solid Tumor Drug Product Portfolio Table 49. Pfizer Inc Recent Development Table 50. GlaxoSmithKline plc. Company Information Table 51. GlaxoSmithKline plc. Business Overview Table 52. GlaxoSmithKline plc. Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio Table 54. GlaxoSmithKline plc. Recent Development Table 55. Baxter Company Information Table 56. Baxter Business Overview Table 57. Baxter Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Baxter Solid Tumor Drug Product Portfolio Table 59. Baxter Recent Development Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. AstraZeneca Solid Tumor Drug Product Portfolio Table 64. AstraZeneca Recent Development Table 65. F. Hoffmann-La Roche Ltd. Company Information Table 66. F. Hoffmann-La Roche Ltd. Business Overview Table 67. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio Table 69. F. Hoffmann-La Roche Ltd. Recent Development Table 70. Eli Lilly and Company Company Information Table 71. Eli Lilly and Company Business Overview Table 72. Eli Lilly and Company Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Eli Lilly and Company Solid Tumor Drug Product Portfolio Table 74. Eli Lilly and Company Recent Development Table 75. Celgene Corporation Company Information Table 76. Celgene Corporation Business Overview Table 77. Celgene Corporation Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Celgene Corporation Solid Tumor Drug Product Portfolio Table 79. Celgene Corporation Recent Development Table 80. Bristol-Myers Squibb Company Company Information Table 81. Bristol-Myers Squibb Company Business Overview Table 82. Bristol-Myers Squibb Company Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio Table 84. Bristol-Myers Squibb Company Recent Development Table 85. Biogen Company Information Table 86. Biogen Business Overview Table 87. Biogen Solid Tumor Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Biogen Solid Tumor Drug Product Portfolio Table 89. Biogen Recent Development Table 90. Amgen Limited & Amgen Ireland Limited Company Information Table 91. Amgen Limited & Amgen Ireland Limited Business Overview Table 92. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio Table 94. Amgen Limited & Amgen Ireland Limited Recent Development Table 95. Abbott Laboratories Company Information Table 96. Abbott Laboratories Business Overview Table 97. Abbott Laboratories Solid Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Abbott Laboratories Solid Tumor Drug Product Portfolio Table 99. Abbott Laboratories Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Solid Tumor Drug Product Image Figure 2. Global Solid Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Solid Tumor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecules Image Figure 8. Biologics Image Figure 9. Global Solid Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Solid Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Solid Tumor Drug Sales Value Share by Type (2021-2032) Figure 12. Radiology Image Figure 13. Neurology Image Figure 14. Oncology Image Figure 15. Others Image Figure 16. Global Solid Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Solid Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Solid Tumor Drug Sales Value Share by Application (2021-2032) Figure 19. Global Solid Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Solid Tumor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Solid Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Solid Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Solid Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Solid Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Solid Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Solid Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Solid Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Solid Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Solid Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Solid Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Solid Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Radiology
  • Neurology
  • Oncology
  • Others
Companies covered
  • Johnson & Johnson
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Baxter
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Biogen
  • Amgen Limited & Amgen Ireland Limited
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Solid Tumor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Solid Tumor Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Solid Tumor Drug Market Dynamics
  1. 2.1 Solid Tumor Drug Industry Trends
  2. 2.2 Solid Tumor Drug Industry Drivers
  3. 2.3 Solid Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Solid Tumor Drug Industry Restraints
3 Solid Tumor Drug Market by Company
  1. 3.1 Global Solid Tumor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Solid Tumor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Solid Tumor Drug Company Ranking (2024-2026)
  4. 3.4 Global Solid Tumor Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Solid Tumor Drug Company Product Type and Application
  6. 3.6 Global Solid Tumor Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Solid Tumor Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Solid Tumor Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Solid Tumor Drug Market by Type
  1. 4.1 Solid Tumor Drug Type Introduction
  2. 4.1.1 Small Molecules
  3. 4.1.2 Biologics
  4. 4.2 Global Solid Tumor Drug Sales Value by Type
  5. 4.2.1 Global Solid Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Solid Tumor Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Solid Tumor Drug Sales Value Share by Type (2021-2032)
5 Solid Tumor Drug Market by Application
  1. 5.1 Solid Tumor Drug Application Introduction
  2. 5.1.1 Radiology
  3. 5.1.2 Neurology
  4. 5.1.3 Oncology
  5. 5.1.4 Others
  6. 5.2 Global Solid Tumor Drug Sales Value by Application
  7. 5.2.1 Global Solid Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Solid Tumor Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Solid Tumor Drug Sales Value Share by Application (2021-2032)
6 Solid Tumor Drug Regional Value Analysis
  1. 6.1 Global Solid Tumor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Solid Tumor Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Solid Tumor Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Solid Tumor Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Solid Tumor Drug Sales Value (2021-2032)
  7. 6.3.2 North America Solid Tumor Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Solid Tumor Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Solid Tumor Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Solid Tumor Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Solid Tumor Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Solid Tumor Drug Sales Value (2021-2032)
  16. 6.6.2 South America Solid Tumor Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Solid Tumor Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Solid Tumor Drug Sales Value Share by Country, 2025 VS 2032
7 Solid Tumor Drug Country-level Value Analysis
  1. 7.1 Global Solid Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Solid Tumor Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Solid Tumor Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Solid Tumor Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Solid Tumor Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Solid Tumor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Solid Tumor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Pfizer Inc
  8. 8.2.1 Pfizer Inc Company Information
  9. 8.2.2 Pfizer Inc Business Overview
  10. 8.2.3 Pfizer Inc Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio
  12. 8.2.5 Pfizer Inc Recent Developments
  13. 8.3 GlaxoSmithKline plc.
  14. 8.3.1 GlaxoSmithKline plc. Company Information
  15. 8.3.2 GlaxoSmithKline plc. Business Overview
  16. 8.3.3 GlaxoSmithKline plc. Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
  18. 8.3.5 GlaxoSmithKline plc. Recent Developments
  19. 8.4 Baxter
  20. 8.4.1 Baxter Company Information
  21. 8.4.2 Baxter Business Overview
  22. 8.4.3 Baxter Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Baxter Solid Tumor Drug Product Portfolio
  24. 8.4.5 Baxter Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Solid Tumor Drug Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 F. Hoffmann-La Roche Ltd.
  32. 8.6.1 F. Hoffmann-La Roche Ltd. Company Information
  33. 8.6.2 F. Hoffmann-La Roche Ltd. Business Overview
  34. 8.6.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
  36. 8.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
  37. 8.7 Eli Lilly and Company
  38. 8.7.1 Eli Lilly and Company Company Information
  39. 8.7.2 Eli Lilly and Company Business Overview
  40. 8.7.3 Eli Lilly and Company Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
  42. 8.7.5 Eli Lilly and Company Recent Developments
  43. 8.8 Celgene Corporation
  44. 8.8.1 Celgene Corporation Company Information
  45. 8.8.2 Celgene Corporation Business Overview
  46. 8.8.3 Celgene Corporation Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
  48. 8.8.5 Celgene Corporation Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Solid Tumor Drug Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Amgen Limited & Amgen Ireland Limited
  62. 8.11.1 Amgen Limited & Amgen Ireland Limited Company Information
  63. 8.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
  64. 8.11.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
  66. 8.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
  67. 8.12 Abbott Laboratories
  68. 8.12.1 Abbott Laboratories Company Information
  69. 8.12.2 Abbott Laboratories Business Overview
  70. 8.12.3 Abbott Laboratories Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
  72. 8.12.5 Abbott Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst